Atlas Trials

Phase IV Observational Study of Orelabrutinib in the Treatment of Chronic Lymphocytic Leukemia/Small Cell Lymphoma

Clinical trial NCT05920668 · UNKNOWN

Trial details

NCT number
NCT05920668
Sponsor
Wang Xin
Status
UNKNOWN
Study type
OBSERVATIONAL
CLL/SLL
Start date
2023-07-01
Primary completion
2024-07-01
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.